Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590837 | 0.79 | MCHR1 (0.41) | CSNK1DCSNK1E | |
| SCHEMBL3582794 | 0.78 | CSNK1D (0.44) | FLT3CSNK1DCSNK1E | |
| SCHEMBL23468402 | 0.76 | PDGFRA (0.73) | FLT3PDGFRA | |
| SCHEMBL21880697 | 0.73 | FLT3 (1.00) | FLT3PDGFRA | |
| SCHEMBL21802046 | 0.71 | FLT3 (1.00) | FLT3PDGFRA | |
| SCHEMBL21802052 | 0.71 | FLT3 (1.00) | FLT3PDGFRA | |
| SCHEMBL20274618 | 0.67 | EGFR (0.58) | — | |
| SCHEMBL4555328 | 0.67 | CHEK2 (0.39) | CSNK1DCSNK1E | |
| SCHEMBL23468405 | 0.66 | FLT3 (0.70) | FLT3PDGFRA | |
| SCHEMBL21802049 | 0.65 | FLT3 (0.80) | FLT3PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | claimed |
| CN-101622001-A | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases | IRM LLC | 2010-01-06 | — | — | CN | claimed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | claimed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| CN-101622001-A | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases | IRM LLC | 2010-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | FLT3 317/4885PDGFRA 1321/4885CSNK1D 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.